Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Alfred

Showing results (181-190 of 434) with videos related to

Pageof 44
Sort By:
BJU International|March 5, 2013
Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS)J Alfred Witjes, Joan Palou, Mark Soloway, et al.
European Urology|August 3, 2013
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literatureMichael Rink, Marko Babjuk, James W F Catto, et al.
The Journal of Urology|April 1, 2014
Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancerAshish M Kamat, J Alfred Witjes, Maurizio Brausi, et al.
World Journal of Urology|May 31, 2015
Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validationRianne J M Lammers, Jan C M Hendriks, O Rodriguez Faba Rodriguez Faba, et al.
Anticancer Research|May 1, 2007
Simultaneous proteomic and genomic analysis of primary Ta urothelial cell carcinomas for the prediction of tumor recurrenceIman J Schultz, Jacques B De Kok, J Alfred Witjes, et al.
International Journal of Cancer|April 1, 2005
CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomasIman J Schultz, Lambertus A Kiemeney, J Alfred Witjes, et al.
European Urology|December 4, 2014
Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic reviewRowan G Casey, James W F Catto, Liang Cheng, et al.
Magma (New York, N.Y.)|November 26, 2008
High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsiesJack J A van Asten, Vincent Cuijpers, Christina Hulsbergen-van de Kaa, et al.
The Journal of Urology|May 16, 2012
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopyH Barton Grossman, Arnulf Stenzl, Yves Fradet, et al.
The Journal of Urology|August 27, 2013
Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definitionDonald Lamm, Raj Persad, Maurizio Brausi, et al.
Pageof 44

Showing results (181-190 of 434) with videos related to

Sort By:
Pageof 44
BJU International|March 5, 2013
Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS)J Alfred Witjes, Joan Palou, Mark Soloway, et al.
European Urology|August 3, 2013
Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literatureMichael Rink, Marko Babjuk, James W F Catto, et al.
The Journal of Urology|April 1, 2014
Defining and treating the spectrum of intermediate risk nonmuscle invasive bladder cancerAshish M Kamat, J Alfred Witjes, Maurizio Brausi, et al.
World Journal of Urology|May 31, 2015
Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validationRianne J M Lammers, Jan C M Hendriks, O Rodriguez Faba Rodriguez Faba, et al.
Anticancer Research|May 1, 2007
Simultaneous proteomic and genomic analysis of primary Ta urothelial cell carcinomas for the prediction of tumor recurrenceIman J Schultz, Jacques B De Kok, J Alfred Witjes, et al.
International Journal of Cancer|April 1, 2005
CDC91L1 (PIG-U) mRNA expression in urothelial cell carcinomasIman J Schultz, Lambertus A Kiemeney, J Alfred Witjes, et al.
European Urology|December 4, 2014
Diagnosis and management of urothelial carcinoma in situ of the lower urinary tract: a systematic reviewRowan G Casey, James W F Catto, Liang Cheng, et al.
Magma (New York, N.Y.)|November 26, 2008
High resolution magic angle spinning NMR spectroscopy for metabolic assessment of cancer presence and Gleason score in human prostate needle biopsiesJack J A van Asten, Vincent Cuijpers, Christina Hulsbergen-van de Kaa, et al.
The Journal of Urology|May 16, 2012
Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopyH Barton Grossman, Arnulf Stenzl, Yves Fradet, et al.
The Journal of Urology|August 27, 2013
Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definitionDonald Lamm, Raj Persad, Maurizio Brausi, et al.
Pageof 44